Glutamate-based amino acid-producing microorganism and glutamate-based amino acid-producing method using same
By culturing Corynebacterium microorganisms with weakened protein activity, the production capacity of glutamate amino acids is enhanced, addressing inefficiencies in existing methods and achieving high-yield industrial production.
Patent Information
- Application Number
- PCT/KR2024/006917
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-23
- Filing Date
- 2024-05-22
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods for producing L-amino acids, particularly glutamate amino acids, are inefficient and require further research to enhance production capacity in microorganisms like Corynebacterium glutamicum.
Culturing a Corynebacterium microorganism with a weakened protein activity containing a specific amino acid sequence (SEQ ID NO: 1) to improve glutamate amino acid production, involving gene modification and protein activity attenuation techniques to increase yield.
The method results in a high-yield production of glutamate series amino acids, such as citrulline, ornithine, arginine, glutamic acid, and proline, making it suitable for industrial applications.
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
Microorganism producing glutamate-series amino acids and method for producing glutamate-series amino acids using the same
[0001] The present application relates to a method for producing glutamate-based amino acids, comprising the step of culturing a Corynebacterium genus microorganism having a glutamate-based amino acid production ability, wherein the activity of a protein comprising an amino acid sequence of SEQ ID NO: 1 is weakened compared to the intrinsic activity; a composition for producing glutamate-based amino acids, comprising the microorganism, a culture of the microorganism, a fermentation product of the microorganism, or a combination of two or more thereof; and a use of the microorganism for producing glutamate-based amino acids.
[0002]
[0003] L-amino acids derived from glutamate, such as L-citrulline, have the function of dilating blood vessels and promoting ammonia excretion in the body (K Takeda et al. 2013), making them industrially useful.
[0004] Microorganisms of the genus Corynebacterium, particularly Corynebacterium glutamicum, are Gram-positive microorganisms widely used for the production of L-amino acids. To produce L-amino acids, target-substance-specific approaches are primarily used, such as increasing the expression level of genes encoding enzymes primarily involved in L-amino acid biosynthesis in Corynebacterium strains or deleting genes unnecessary for L-amino acid biosynthesis (US 9644009 B2). However, research into methods capable of efficiently producing L-amino acids remains a pressing need.
[0005] Therefore, research is still needed to effectively increase glutamate-based amino acid production.
[0006]
[0007] The purpose of the present application is to provide a microorganism producing glutamate series amino acids and a method for producing glutamate series amino acids using the same.
[0008]
[0009] One aspect of the present application provides a method for producing a glutamate series amino acid, comprising the step of culturing a microorganism of the genus Corynebacterium having a glutamate series amino acid production ability, wherein the activity of a protein comprising the amino acid sequence of SEQ ID NO: 1 is weakened compared to the intrinsic activity, in a medium.
[0010] In one specific example, a protein comprising the amino acid sequence of SEQ ID NO: 1 may be encoded by a gene comprising the base sequence of SEQ ID NO: 2.
[0011] As a microorganism according to any one of the preceding specific examples, the microorganism of the genus Corynebacterium may be Corynebacterium glutamicum.
[0012] In another specific embodiment, the method may additionally include a step of recovering glutamate series amino acids from the cultured microorganism, a culture of the microorganism, a fermented product of the microorganism, or the culture medium.
[0013] In another specific example, the glutamate series amino acid may be selected from the group consisting of citrulline, ornithine, arginine, glutamic acid, proline, and combinations thereof.
[0014] Another aspect of the present application provides a composition for producing glutamate-series amino acids, comprising a Corynebacterium genus microorganism having a glutamate-series amino acid production ability in which the activity of a protein comprising the amino acid sequence of SEQ ID NO: 1 is weakened compared to the intrinsic activity, a culture of the microorganism, a fermentation product of the microorganism, or a combination of two or more thereof.
[0015]
[0016] A microorganism of the genus Corynebacterium having a glutamate series amino acid production ability that is weakened compared to the intrinsic activity of a protein including the amino acid sequence of sequence number 1 of the present application can produce glutamate series amino acids at a high yield, and thus can be usefully utilized in the industrial production of glutamate series amino acids.
[0017]
[0018] This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in this application can also be applied to each other description and embodiment. In other words, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application is not limited by the specific descriptions described below.
[0019] Furthermore, those skilled in the art will recognize or be able to ascertain, using only routine experimentation, numerous equivalents to the specific embodiments of the present application described herein. Furthermore, such equivalents are intended to be encompassed by this application.
[0020] As used in the specification and appended claims of this application, the singular articles "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Unless the context clearly dictates otherwise, the singular terms include the plural and the plural terms include the singular. In the specification and appended claims of this application, unless the context clearly dictates otherwise, the use of "or" is intended to include "and / or."
[0021]
[0022] In this application, the term "about" may be used before a specific numerical value. As used herein, the term "about" encompasses not only the exact number described after the term, but also a range that is or is nearly that number. Whether a number is or is nearly the specific number described can be determined based on the context in which it is presented. For example, the term "about" may refer to a range of -10% to +10% of a numerical value. In another example, the term "about" may refer to a range of -5% to +5% of a given numerical value. However, this is not a limitation.
[0023] In this application, the terms "first, second, third," "i), ii), iii),," or "(a), (b), (c), (d),," are used to distinguish similar configurations, and these terms do not imply that the steps are performed consecutively or in order. For example, when the terms are used in connection with steps of a method, use, or analysis, these steps may be performed simultaneously, or may be performed at intervals of seconds, minutes, hours, days, or months.
[0024] In this application, the term "consisting essentially of" means that a non-specific component may be present if the characteristics of the subject matter claimed in this application are not substantially affected by the presence of the non-specific component.
[0025] In this application, the term "consisting of" means that the proportion of a specific component(s) totals 100%. The components or features listed below the term "consisting of" may be essential or mandatory. In some embodiments, other than the components or features listed below "consisting of," other optional or nonessential components may be excluded.
[0026] In this application, the term "comprising" means the presence of a feature, step, or component described below, and does not exclude the presence or addition of one or more features, steps, or components. The components or features described below "comprising" in this application may be essential or mandatory, but in some embodiments, other optional or non-essential components or features may be further included.
[0027]
[0028] One aspect of the present application provides a method for producing a glutamate series amino acid, comprising the step of culturing a microorganism of the genus Corynebacterium having a glutamate series amino acid production ability, wherein the activity of a protein comprising the amino acid sequence of SEQ ID NO: 1 is weakened compared to the intrinsic activity, in a medium.
[0029]
[0030] In this application, the term "protein comprising the amino acid sequence of SEQ ID NO: 1" means a protein endogenously present in a microorganism of the genus Corynebacterium or a hypothetical protein of unknown function.
[0031] Specifically, the protein comprising the amino acid sequence of SEQ ID NO: 1 of the present application may be a protein having the activity of the protein comprising the amino acid sequence of SEQ ID NO: 1 encoded by a gene comprising the base sequence of SEQ ID NO: 2, but is not particularly limited in type as long as it has an activity corresponding to the protein comprising the amino acid sequence of SEQ ID NO: 1 and its activity is weakened compared to the intrinsic activity in a microorganism of the genus Corynebacterium to improve the productivity of glutamate series amino acids. The protein comprising the amino acid sequence of SEQ ID NO: 1 encoded by the gene comprising the base sequence of SEQ ID NO: 2 is known in the art, and the amino acid and polynucleotide sequences of the protein comprising the amino acid sequence of SEQ ID NO: 1 can be obtained from a known database, such as, but not limited to, NCBI's GenBank.
[0032] In the present application, the protein comprising the amino acid sequence of sequence number 1 may be a protein comprising the amino acid sequence of sequence number 1 derived from a microorganism of the genus Corynebacterium (Corynebacterium sp.), specifically, from Corynebacterium glutamicum, but is not limited thereto.
[0033] For example, a protein comprising the amino acid sequence of SEQ ID NO: 1 may comprise the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 60% homology or identity therewith, but is not limited thereto, as long as it has a protein activity comprising the amino acid sequence of SEQ ID NO: 1. Specifically, a polypeptide having a protein activity comprising the amino acid sequence of SEQ ID NO: 1 may have, comprise, consist of, or consist essentially of SEQ ID NO: 1 or an amino acid sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology or identity therewith. For example, a protein comprising the amino acid sequence of the above sequence number 1 may refer to a protein endogenously present in a microorganism of the genus Corynebacterium or Corynebacterium glutamicum, but is not limited thereto.
[0034] In the present application, with respect to the amino acid sequence, even if it is described as a polypeptide “comprising” the amino acid sequence set forth in a specific sequence number, a polypeptide “consisting of” the amino acid sequence set forth in a specific sequence number, or a polypeptide or protein “having” the amino acid sequence set forth in a specific sequence number, it is obvious that a protein having an amino acid sequence in which a portion of the sequence is deleted, modified, substituted, conservatively substituted, or added is also included within the scope of the present application, as long as it has the same or corresponding activity as the protein consisting of the amino acid sequence of the corresponding sequence number. For example, if it has the same or corresponding activity as the above-mentioned mutant protein, it does not exclude sequence additions that do not alter the function of the protein before or after the amino acid sequence, mutations that may occur naturally, silent mutations thereof, or conservative substitutions, and it is obvious that even if it has such sequence additions or mutations, it is also within the scope of the present application.
[0035] For example, the variant polypeptide of the present invention may have sequence additions, naturally occurring mutations, silent mutations, or conservative substitutions at the N-terminus, C-terminus, and / or within the amino acid sequence that do not alter the function of the polypeptide. For example, the polypeptide may be conjugated to a signal (or leader) sequence at the N-terminus of a protein that is involved in the transfer of the protein co-translationally or post-translationally. Furthermore, the polypeptide may be conjugated to other sequences or linkers so that the polypeptide can be identified, purified, or synthesized.
[0036] In this application, the term "conservative substitution" refers to the replacement of one amino acid with another amino acid having similar structural and / or chemical properties. Such amino acid substitutions may generally occur based on similarities in the polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues. For example, positively charged (basic) amino acids include arginine, lysine, and histidine; negatively charged (acidic) amino acids include glutamic acid and aspartic acid; and amino acids with nonpolar side chains (nonpolar amino acids) include glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, and proline; Amino acids with polar or hydrophilic side chains (polar amino acids) include serine, threonine, cysteine, tyrosine, asparagine, and glutamine. As another example, amino acids with charged side chains include arginine, lysine, histidine, glutamic acid, and aspartic acid, while amino acids with uncharged side chains (also called neutral amino acids) include glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. As another example, phenylalanine, tryptophan, and tyrosine can be classified as aromatic amino acids. As another example, valine, leucine, and isoleucine can be classified as branched amino acids.As another example, the 20 amino acids can be classified into five groups based on size: glycine, alanine, and serine; cysteine, proline, threonine, aspartic acid, and asparagine; valine, histidine, glutamic acid, and glutamine; isoleucine, leucine, methionine, lysine, and arginine; and phenylalanine, tryptophan, and tyrosine. However, this is not necessarily limited to these groups. Typically, conservative substitutions may have little or no effect on the activity of the polypeptide.
[0037]
[0038] In addition, the base sequence encoding a protein including the amino acid sequence of the above sequence number 1 may be a base sequence encoding a protein that exhibits the activity of the protein including the amino acid sequence of the sequence number 1, and whose activity is weakened compared to the intrinsic activity in a microorganism of the genus Corynebacterium, thereby enhancing the productivity of glutamate-based amino acids. For example, the base sequence may be, but is not limited to, the NCgl2914 gene, which is a gene endogenously present in a microorganism of the genus Corynebacterium, but which encodes a hypothetical protein of unknown function.
[0039] For example, a protein comprising the amino acid sequence of SEQ ID NO: 1 may be encoded by a polynucleotide having or including a base sequence having at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and less than 100% homology or identity with the base sequence of SEQ ID NO: 2, or consisting of or consisting essentially of the base sequence, but is not limited thereto. In addition, the base sequence of SEQ ID NO: 2 can be obtained from a known database, such as, but not limited to, NCBI's GenBank.
[0040] In the present application, the gene comprising the base sequence of SEQ ID NO: 2 may be used interchangeably with a polynucleotide comprising the base sequence of SEQ ID NO: 2, a gene or polynucleotide having the base sequence of SEQ ID NO: 2, a gene or polynucleotide consisting of the base sequence of SEQ ID NO: 2, or the NCgl2914 gene.
[0041] The polynucleotide of the present application may have various modifications in the coding region within a range that does not change the amino acid sequence of the protein comprising the amino acid sequence of SEQ ID NO. 1 of the present application due to codon degeneracy or in consideration of the codons preferred in an organism that is intended to express a protein comprising the amino acid sequence of SEQ ID NO. 1 of the present application. Therefore, it is obvious that the polynucleotide of the present application may also be included, which can be translated into a polypeptide consisting of the amino acid sequence of the protein comprising the amino acid sequence of SEQ ID NO. 1 of the present application or a polypeptide having homology or identity therewith due to codon degeneracy. For example, the polynucleotide of the present application may be SEQ ID NO. 2 or a degenerated sequence thereof.
[0042] In addition, the polynucleotide of the present application may include, without limitation, a probe that can be prepared from a known gene sequence, for example, a sequence that hybridizes under stringent conditions with a complementary sequence to all or part of the polynucleotide sequence of the present application, and encodes a protein comprising the amino acid sequence of SEQ ID NO. 1 of the present application.
[0043] As used herein, the terms "homology" or "identity" refer to the degree of relationship between two given amino acid sequences or base sequences, which may be expressed as a percentage. The terms homology and identity are often used interchangeably.
[0044] Sequence homology or identity of conserved polynucleotides or polypeptides is determined by standard alignment algorithms, and may be combined with default gap penalties established by the program being used. In practice, homologous or identical sequences are generally capable of hybridizing under moderate or high stringency conditions, typically along at least about 50%, 60%, 70%, 80%, or 90% of the entire sequence or its entire length. It should be appreciated that hybridization also encompasses polynucleotides containing common codons or codons that are considered codon degenerate.
[0045] Whether any two polynucleotide or polypeptide sequences are homologous, similar or identical can be determined using known computer algorithms such as the "FASTA" program using default parameters, for example as in Pearson et al (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444. Alternatively, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (version 5.0.0 or later) can be determined using the GCG program package (Devereux, J., et al, Nucleic Acids Research 12: 387 (1984)), BLASTP, BLASTN, FASTA (Atschul, [S.] [F.,] [ET AL, J MOLEC BIOL 215]: 403 (1990); Guide to Huge Computers, Martin J. Bishop, [ED.,] Academic Press, San Diego, 1994, and [CARILLO et al.](1988) SIAM J Applied Math 48: 1073). For example, homology, similarity, or identity can be determined using BLAST or ClustalW from the National Center for Biotechnology Information database.
[0046] Homology, similarity or identity of polynucleotides or polypeptides can be determined by comparing sequence information using, for example, the GAP computer program disclosed in Smith and Waterman, Adv. Appl. Math (1981) 2:482, or, for example, Needleman et al. (1970), J Mol Biol. 48:443. In brief, the GAP program can be defined as the total number of symbols in the shorter of the two sequences divided by the number of similarly arranged symbols (i.e., nucleotides or amino acids). The default parameters for the GAP program are (1) unitary matrices (containing values of 1 for identity and 0 for non-identity), the PAM Matrix (see the disclosure by Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation (1978)), Gribskov et al (1986) Nucl. Acids Res. 14: 6745 weighted comparison matrix (or EDNAFULL (EMBOSS version of NCBI NUC4.4) permutation matrix); (2) a penalty of 3.0 for each gap and an additional penalty of 0.10 for each symbol in each gap (or a gap opening penalty of 10, a gap extension penalty of 0.5); and (3) no penalty for terminal gaps.
[0047] Additionally, whether any two polynucleotide or polypeptide sequences have homology, similarity or identity can be determined by comparing the sequences by Southern hybridization experiments under defined stringent conditions, and the defined appropriate hybridization conditions are within the scope of the art and can be determined by methods well known to those skilled in the art (e.g., J. Sambrook et al., Molecular Cloning, A Laboratory Manual; F. M. Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York), but are not limited thereto.
[0048] In this application, the term "stringent conditions" refers to conditions that allow specific hybridization between polynucleotides. Such conditions are specifically described in the literature (see Sambrook et al., supra, 9.50-9.51, 11.7-11.8). For example, conditions in which polynucleotides having high homology or identity hybridize with each other, polynucleotides having 60% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more homology or identity hybridize with each other, and polynucleotides having lower homology or identity do not hybridize with each other, or conditions in which washing is performed once, specifically twice or three times, at a salt concentration and temperature equivalent to 60°C, 1ХSSC, 0.1% SDS, specifically 60°C, 0.1ХSSC, 0.1% SDS, and more specifically 68°C, 0.1ХSSC, 0.1% SDS, which are washing conditions of typical southern hybridization, are performed.
[0049] The above hybridization requires that the two nucleotides have complementary sequences, although mismatches between bases are possible depending on the stringency of the hybridization. The term "complementary" is used to describe the relationship between nucleotide bases that can hybridize with each other. For example, in DNA, adenosine is complementary to thymine, and cytosine is complementary to guanine. Accordingly, the polynucleotide of the present application may also include isolated nucleic acid fragments that are complementary in their entirety, as well as those with substantially similar base sequences.
[0050] For example, a polynucleotide having homology or identity with the polynucleotide of the present application can be detected using hybridization conditions including a hybridization step at a Tm value of 55°C and using the conditions described above. In addition, the Tm value may be, but is not limited to, 60°C, 63°C, or 65°C, and can be appropriately adjusted by a person skilled in the art depending on the purpose.
[0051] The appropriate stringency for hybridizing the polynucleotides depends on the length and degree of complementarity of the polynucleotides, variables which are well known in the art (e.g., J. Sambrook et al., supra).
[0052]
[0053] In one specific example, the glutamate series amino acid of the present application may be selected from the group consisting of, but is not limited to, citrulline, ornithine, arginine, glutamic acid, proline, and combinations thereof.
[0054] For example, the glutamate series amino acid of the present application may be, but is not limited to, L-citrulline.
[0055]
[0056] In this application, the term "microorganism (or strain)" includes both wild-type microorganisms and microorganisms that have undergone genetic modification, either naturally or artificially. It may be a microorganism that has a specific mechanism weakened or increased due to causes such as the insertion of an external gene or the increased or inactivated activity of an endogenous gene, and may be a microorganism that includes genetic modification for the production of a desired polypeptide, protein, or product. In this application, "microorganism" and "strain" may be used interchangeably without limitation with the same meaning.
[0057]
[0058] In the present application, the term "microorganism having the ability to produce glutamate-series amino acids" refers to a prokaryotic or eukaryotic microbial strain capable of producing glutamate-series amino acids within the organism, and may include both a microorganism in which the ability to produce glutamate-series amino acids has been conferred on a parent strain that does not have the ability to produce glutamate-series amino acids, and a microorganism that inherently has the ability to produce glutamate-series amino acids. The ability to produce glutamate-series amino acids may be conferred or enhanced by species improvement.
[0059] For example, the microorganism having the ability to produce glutamate-based amino acids of the present application may be a microorganism (e.g., a recombinant strain) in which the activity of a protein comprising the amino acid sequence of SEQ ID NO: 1 is weakened compared to the intrinsic activity, but is not limited thereto.
[0060] In this application, the term "unmodified microorganism" does not exclude a strain that contains a mutation that can occur naturally in a microorganism, and may refer to a wild-type strain or a natural strain itself, or a strain before its characteristics are changed by genetic mutation due to natural or artificial factors. The "unmodified microorganism" may be used interchangeably with "pre-modified strain", "pre-modified microorganism", "unmodified strain", "unmodified strain", "unmodified microorganism", "pre-mutated parent strain", "wild-type microorganism", "reference microorganism", or "reference microorganism". In this application, the unmodified microorganism may refer to a strain in which the activity of a protein comprising the amino acid sequence of SEQ ID NO: 1 of this application is not weakened compared to the intrinsic activity, or before the activity of a protein comprising the amino acid sequence of SEQ ID NO: 1 is weakened compared to the intrinsic activity, but is not limited thereto. Additionally, in the present application, the non-modified microorganism may be a microorganism comprising an amino acid sequence consisting of SEQ ID NO: 1 or a polynucleotide consisting of SEQ ID NO: 2, but is not limited thereto.
[0061] For the purposes of this application, the unmodified microorganism of this application is inherently
[0062] i) a protein comprising an amino acid sequence of SEQ ID NO: 1, or a protein comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7% or 99.9% homology or identity with the amino acid sequence of SEQ ID NO: 1; and / or
[0063] ii) It may be a microorganism comprising a polynucleotide sequence capable of encoding a protein comprising an amino acid sequence having at least 80% homology with sequence number 1, a base sequence of sequence number 2, or a base sequence having 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, and less than 100% homology or identity with the base sequence of sequence number 2.
[0064]
[0065] For the purpose of the present application, the microorganism of the present application may include any microorganism capable of producing a desired glutamate-series amino acid by weakening the activity of a protein comprising the amino acid sequence of SEQ ID NO: 1 compared to the intrinsic activity. For example, the microorganism of the present application is characterized by having an increased ability to produce glutamate-series amino acids by weakening the activity of a protein comprising the amino acid sequence of SEQ ID NO: 1 compared to the intrinsic activity, and may be a genetically modified microorganism or a recombinant microorganism, but is not limited thereto. Specifically, the recombinant strain with increased ability to produce glutamate-series amino acids may be a microorganism with increased ability to produce glutamate-series amino acids compared to a natural wild-type microorganism or an unmodified microorganism having the intrinsic activity of a protein comprising the amino acid sequence of SEQ ID NO: 1, but is not limited thereto.
[0066] For example, a microorganism having the ability to produce glutamate-series amino acids may include a prokaryotic or eukaryotic microorganism strain capable of producing glutamate-series amino acids within the organism, and may include a microorganism endowed with the ability to produce glutamate-series amino acids due to a protein activity comprising the amino acid sequence of SEQ ID NO: 1 that is weakened compared to the intrinsic activity of a parent strain that does not have the ability to produce glutamate-series amino acids. The ability to produce glutamate-series amino acids may be endowed or enhanced by species improvement.
[0067] The microorganism of the present application may include all microorganisms in which the activity of a protein comprising the amino acid sequence of sequence number 1 is weakened compared to the intrinsic activity by various known methods.
[0068]
[0069] The above “intrinsic activity” refers to the activity of a specific polypeptide originally possessed by the parent strain or unmodified microorganism before the change in trait when the trait is changed due to genetic mutation caused by natural or artificial factors. This may be used interchangeably with “activity before modification.”
[0070] In this application, the term "weakening" of polypeptide activity encompasses both weakening of activity or absence of activity compared to the intrinsic activity. The term "weakening" may be used interchangeably with terms such as deficiency, inactivation, deletion, disruption, down-regulation, decrease, attenuation, repression, and reduction.
[0071] For example, the attenuation of the polypeptide activity may include a state in which the polypeptide activity is exhibited within the host cell (microorganism) but is not completely inactivated by deletion, such that the polypeptide activity is reduced compared to the intrinsic activity or the activity before modification; or the polypeptide expression may not be expressed at all or, even if expressed, the activity is absent or reduced (inactivated) compared to the host cell (microorganism) before transformation or the unmodified microorganism.
[0072] The above weakening may also include cases where the activity of the polypeptide itself is weakened or eliminated compared to the activity of the polypeptide originally possessed by the microorganism due to mutation of the polynucleotide encoding the polypeptide, etc., cases where the overall level of polypeptide activity within the cell is lower than that of the natural strain due to inhibition of expression of the gene encoding the polypeptide or inhibition of translation into the polypeptide, cases where the gene is not expressed at all, and cases where the polypeptide has no activity even if the gene is expressed.
[0073] A weakening of a polypeptide's activity relative to its intrinsic activity means that the activity of a specific polypeptide is lower than that originally possessed by the parent strain or unmodified microorganism prior to transformation. Whether the polypeptide's activity is weakened can be determined by examining the degree of activity, expression level, or the amount of product secreted from the polypeptide.
[0074] For example, the weakening may be, but is not limited to, that the activity of the protein comprising the amino acid sequence of SEQ ID NO: 1 is less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%, less than about 5%, or 0% of the activity of the protein comprising the amino acid sequence of SEQ ID NO: 1 of the parent strain or unmodified microorganism before the transformation.
[0075] For example, the above inactivation may mean that the expression of a protein containing the amino acid sequence of sequence number 1 is not expressed at all compared to a non-modified microorganism, or even if it is expressed, the activity is absent or weakened.
[0076] Attenuation of the activity of such polypeptides can be accomplished by any method known in the art, including but not limited to, and can be achieved by application of various methods well known in the art (e.g., Nakashima N et al., Bacterial cellular engineering by genome editing and gene silencing. Int J Mol Sci. 2014;15(2):2773-2793, Sambrook et al. Molecular Cloning 2012, etc.).
[0077] Specifically, the weakening of the polypeptide activity of the present application is
[0078] 1) Deletion of all or part of a gene encoding a polypeptide;
[0079] 2) Modification of the expression control region (or expression control sequence) so as to weaken the expression of the gene encoding the polypeptide;
[0080] 3) Modification of the amino acid sequence constituting the polypeptide (e.g., deletion / substitution / addition of one or more amino acids in the amino acid sequence) so as to eliminate or weaken the activity of the polypeptide;
[0081] 4) Modification of a polynucleotide sequence encoding the polypeptide such that the activity of the polypeptide is eliminated or weakened (e.g., deletion / substitution / addition of one or more nucleotides on the nucleotide sequence of the polypeptide gene such that the polypeptide is modified such that the activity of the polypeptide is eliminated or weakened);
[0082] 5) Modification of the initiation codon or 5'-UTR region base sequence of a gene encoding a polypeptide;
[0083] 6) Introduction of an antisense oligonucleotide (e.g., antisense RNA) that complementarily binds to a transcript of the gene encoding the polypeptide;
[0084] 7) Addition of a sequence complementary to the Shine-Dalgarno sequence in front of the Shine-Dalgarno sequence of a gene encoding a polypeptide to form a secondary structure that prevents attachment of ribosomes;
[0085] 8) Addition of a promoter transcribed in the opposite direction to the 3' end of the open reading frame (ORF) of the polynucleotide sequence encoding the polypeptide (Reverse transcription engineering, RTE); or
[0086] 9) Control of cellular localization of proteins (polypeptides); or
[0087] 10) It may be a combination of two or more of the above 1) to 9), but is not particularly limited thereto.
[0088] for example,
[0089] The above 1) deletion of part or all of the gene encoding the polypeptide may be the removal of the entire polynucleotide encoding the endogenous target polypeptide in the chromosome, replacement with a polynucleotide having a partial nucleotide sequence deleted, or replacement with a marker gene.
[0090] Methods for deleting part or all of a polynucleotide include, but are not limited to, deleting the polynucleotide by homologous recombination using a vector for chromosomal insertion into a microorganism, inducing mutations using light such as ultraviolet rays or chemicals, and selecting a strain with a deletion of the target gene from the resulting mutants. The method for deleting part or all of the gene may include a method using DNA recombination technology. For example, a nucleotide sequence or vector containing a nucleotide sequence homologous to the target gene may be injected into the microorganism to cause homologous recombination, thereby causing deletion of part or all of the gene. The injected nucleotide sequence or vector may include, but is not limited to, a dominant selection marker.
[0091] In addition, the above 2) modification of the expression control sequence may be a mutation in the expression control region (or expression control sequence) by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, or replacement with a sequence having weaker activity. The expression control region includes, but is not limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence regulating the termination of transcription and translation.
[0092] In addition, the modification of the amino acid sequence or polynucleotide sequence of the above 3) and 4) may be, but is not limited to, a mutation in the sequence of the amino acid sequence of the polypeptide or the polynucleotide sequence encoding the polypeptide, such as deletion, insertion, non-conservative or conservative substitution, or a combination thereof, so as to weaken the activity of the polypeptide, or replacement with an amino acid sequence or polynucleotide sequence improved to have weaker activity, or an amino acid sequence or polynucleotide sequence improved to have no activity. For example, the expression of a gene may be inhibited or weakened by introducing a mutation in the polynucleotide sequence to form a stop codon, but is not limited thereto.
[0093] In addition, the above 5) modification of the base sequence of the initiation codon or 5'-UTR region of the gene encoding the polypeptide may be, for example, a substitution with another initiation codon having a lower polypeptide expression rate than the endogenous initiation codon, but is not limited thereto.
[0094] The introduction of an antisense oligonucleotide (e.g., antisense RNA) that complementarily binds to the transcript of the gene encoding the polypeptide 6) above can be described, for example, with reference to the literature [Weintraub, H. et al., Antisense-RNA as a molecular tool for genetic analysis, Reviews - Trends in Genetics, Vol. 1(1) 1986].
[0095] 7) Addition of a sequence complementary to the Shine-Dalgarno sequence in front of the Shine-Dalgarno sequence of a gene encoding a polypeptide to form a secondary structure that makes attachment of ribosomes impossible may make mRNA translation impossible or slow it down.
[0096] 8) Addition of a promoter transcribed in the opposite direction to the 3' end of the ORF (open reading frame) of the polynucleotide sequence encoding the polypeptide (Reverse transcription engineering, RTE) may weaken the activity by creating an antisense nucleotide complementary to the transcript of the gene encoding the polypeptide.
[0097] The above 9) regulation of the intracellular location of a protein (polypeptide) may target the protein (polypeptide) to a specific organelle or specific intracellular space within the cell. For example, targeting to the periplasm or cytoplasm may be achieved by adding or removing a leader sequence that functions in targeting the protein (polypeptide), but is not limited thereto.
[0098] Such attenuation of polypeptide activity may include, but is not limited to, a decrease in the activity or concentration or expression level of the corresponding polypeptide relative to the activity or concentration of the polypeptide expressed in the wild type or pre-transformed microbial strain, or a decrease in the amount of a product produced from the polypeptide.
[0099]
[0100] In the microorganism of the present application, modification of part or all of the polynucleotide may be induced by, but is not limited to, (a) homologous recombination using a vector for chromosome insertion into the microorganism or genome editing using engineered nucleases (e.g., CRISPR-Cas9) and / or (b) treatment with light and / or chemicals such as ultraviolet rays and radiation. The method for modifying part or all of the gene may include a method using DNA recombination technology. For example, a nucleotide sequence or vector containing a nucleotide sequence homologous to a target gene may be injected into the microorganism to cause homologous recombination, thereby causing deletion of part or all of the gene. The injected nucleotide sequence or vector may include, but is not limited to, a dominant selection marker.
[0101]
[0102] For example, the recombinant microorganism having the ability to produce glutamate-series amino acids of the present application may include any microorganism that has been transformed with a vector and has a weakened protein activity including the amino acid sequence of SEQ ID NO: 1 of the present application, thereby being capable of producing glutamate-series amino acids.
[0103] The vector of the present application may comprise a DNA construct comprising a base sequence of a polynucleotide encoding a target polypeptide operably linked to a suitable expression control region (or expression control sequence) so as to enable expression of the target polypeptide in a suitable host. The expression control region may comprise a promoter capable of initiating transcription, an optional operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome binding site, and sequences regulating the termination of transcription and translation. The vector may be capable of replicating or functioning independently of the host genome after being transformed into a suitable host cell, or may be integrated into the genome itself.
[0104] The vector used in the present application is not particularly limited, and any vector known in the art can be used. Examples of commonly used vectors include plasmids, cosmids, viruses, and bacteriophages in a natural or recombinant state. For example, pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, and Charon21A can be used as phage vectors or cosmid vectors, and pDZ series, pBR series, pUC series, pBluescriptII series, pGEM series, pTZ series, pCL series, pSK series, pSKH series, and pET series can be used as plasmid vectors. Specifically, pDZ, pDC, pDCM2, pACYC177, pACYC184, pCL, pSK, pSKH130, pECCG117, pUC19, pBR322, pMW118, pCC1BAC vectors, etc. can be used.
[0105] For example, a polynucleotide encoding a target polypeptide can be inserted into a chromosome via a vector for intracellular chromosomal insertion. The insertion of the polynucleotide into the chromosome can be achieved by any method known in the art, for example, homologous recombination, but is not limited thereto. A selection marker for confirming the chromosomal insertion can be additionally included. The selection marker is used to select cells transformed with the vector, i.e., to confirm the insertion of the target nucleic acid molecule. Markers that confer a selectable phenotype, such as drug resistance, nutrient requirement, cytotoxic agent resistance, or expression of a surface polypeptide, can be used. In an environment treated with a selective agent, only cells expressing the selection marker survive or exhibit other phenotypic traits, so that transformed cells can be selected.
[0106] The term "transformation" in this application refers to introducing a vector containing a polynucleotide encoding a target polypeptide into a host cell or microorganism so that the polypeptide encoded by the polynucleotide can be expressed in the host cell. The transformed polynucleotide may be located within the chromosome of the host cell or located extrachromosomally, as long as it can be expressed in the host cell. In addition, the polynucleotide includes DNA and / or RNA encoding the target polypeptide. The polynucleotide may be introduced in any form as long as it can be introduced into the host cell and expressed. For example, the polynucleotide may be introduced into the host cell in the form of an expression cassette, which is a genetic construct containing all elements necessary for autonomous expression. The expression cassette may typically include a promoter, a transcription termination signal, a ribosome binding site, and a translation termination signal, all of which are operably linked to the polynucleotide. The above expression cassette may be in the form of a self-replicating expression vector. Furthermore, the polynucleotide may be introduced into a host cell in its own form and operably linked to a sequence necessary for expression in the host cell, but is not limited thereto.
[0107] As used herein, the term "operably linked" refers to a configuration in which a regulatory sequence is positioned appropriately to direct the expression of a coding sequence. Therefore, "operably linked" includes a regulatory region of a functional domain with known or desired activity, such as a promoter, terminator, signal sequence, or enhancer region, attached or linked to a target (gene or polypeptide) so as to regulate the expression, secretion, or function of the target in accordance with said known or desired activity. For example, it refers to a polynucleotide sequence that is operatively linked to a promoter sequence that initiates and mediates transcription of the polynucleotide encoding the target variant polypeptide of the present application.
[0108] As used herein, the term “expression” includes, but is not limited to, any step involved in the production of a polypeptide, such as transcription, post-transcriptional modification, translation, post-translational modification, and secretion.
[0109] As used herein, the term "expression vector" means a linear or circular nucleic acid molecule comprising a coding sequence and regulatory sequences operably linked thereto for expression thereof.
[0110] As used herein, the term "regulatory sequence" refers to a polynucleotide sequence necessary for the expression of a coding sequence. Each regulatory sequence may be native to the coding sequence (having the same origin) or foreign (derived from another gene). Examples of the regulatory sequence include a leader sequence, a polyadenylation sequence, a propeptide sequence, a promoter, a signal peptide sequence, an operator sequence, a sequence encoding a ribosome binding site, and sequences that regulate transcription and translation termination. The minimum unit of the regulatory sequence may include a promoter, a transcription and translation termination sequence.
[0111] In relation to a cell, polynucleotide, polypeptide, or vector, the term "recombinant" in this application means that the cell, polynucleotide, polypeptide, or vector has been modified by the introduction of a heterologous nucleic acid or polypeptide or by alteration of a native polynucleotide or polypeptide, or that the cell is derived from a cell so modified. Thus, for example, a recombinant cell may express a gene not found in the native (non-recombinant) form of the cell, or may express a native gene that is expressed or not expressed at all, or otherwise abnormally expressed.
[0112]
[0113] The microorganism of the present application may include all microorganisms in which the activity of a protein comprising the amino acid sequence of sequence number 1 is weakened compared to the intrinsic activity by various known methods.
[0114] As a specific example, the microorganism having a weakened activity of a protein comprising the amino acid sequence of SEQ ID NO: 1 of the present application compared to its intrinsic activity may be a microorganism having a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 1 that is missing or modified, but is not limited thereto. Specifically, the microorganism may be a microorganism having a missing base sequence of SEQ ID NO: 2 that lacks the activity of a protein comprising the amino acid sequence of SEQ ID NO: 1, but is not limited thereto.
[0115]
[0116] For example, the microorganism with increased glutamate series amino acid production ability of the present application may be a microorganism with increased glutamate series amino acid production ability compared to a non-modified microorganism, but is not limited thereto. For example, the non-modified microorganism, which is a target strain for comparing whether the glutamate series amino acid production ability is increased, may be a C. gl::argR*_argG* strain, but is not limited thereto.
[0117] For example, the microorganism with increased glutamate series amino acid production ability may have an increase of about 1% or more, specifically, about 1% or more, about 2.5% or more, about 5% or more, about 6% or more, about 7% or more, about 8% or more, about 9% or more, about 10% or more, about 11% or more, about 12% or more, about 13% or more, about 14% or more, about 15% or more, about 16% or more, or about 17% or more (the upper limit is not particularly limited, and may be, for example, about 200% or less, about 150% or less, about 100% or less, about 50% or less, about 45% or less, about 40% or less, about 35% or less, about 30% or less, about 25% or less, or about 20% or less) compared to the glutamate series amino acid production ability of the parent strain or the non-mutated microorganism before mutation. As long as it has a + value increase compared to the productivity of the parent strain or the unmodified microorganism, it is not limited thereto. In another example, the recombinant strain with increased glutamate series amino acid productivity may have an increased glutamate series amino acid productivity of about 1.1 times or more, about 1.11 times or more, about 1.12 times or more, about 1.13 times or more, about 1.14 times or more, about 1.15 times or more, about 1.16 times or more, or about 1.17 times or more (the upper limit is not particularly limited, and may be, for example, about 10 times or less, about 5 times or less, about 3 times or less, about 2 times or less, about 1.5 times or less, about 1.4 times or less, about 1.3 times or less, or about 1.2 times or less) compared to the parent strain before mutation or the unmodified microorganism, but is not limited thereto.
[0118]
[0119] For example, the microorganism having the ability to produce the glutamate series amino acids may be either a prokaryotic cell or a eukaryotic cell, but may specifically be a prokaryotic cell. The prokaryotic cell may include, for example, a microbial strain belonging to the genus Escherichia sp., Erwinia sp., Serratia sp., Providencia sp., Corynebacteria sp., Pseudomonas sp., Leptospirasp., Salmonella sp., Brevibacteria sp., Hypomononas sp., Chromobacterium sp., and Norcardia sp., or a fungus or yeast. Specifically, it is a strain of a microorganism belonging to the genus Escherichia, the genus Corynebacterium, and the genus Leptospira, as well as yeast. More specifically, it may be a strain of a microorganism belonging to the genus Corynebacterium.
[0120] As a microorganism according to any one of the preceding specific examples, the microorganism of the present application may be a microorganism of the genus Corynebacterium.
[0121] As an example of the present application, the microorganism of the present application is Corynebacterium glutamicum, Corynebacterium crudilactis, Corynebacterium deserti, Corynebacterium efficiens, Corynebacterium callunae, Corynebacterium stationis, Corynebacterium singulare, Corynebacterium halotolerans, Corynebacterium striatum, Corynebacterium ammoniagenes, Corynebacterium It may be Corynebacterium pollutisoli, Corynebacterium imitans, Corynebacterium testudinoris, or Corynebacterium flavescens. Specifically, the microorganism of the present application may be a microorganism of the genus Corynebacterium, more specifically, Corynebacterium glutamicum or Corynebacterium stationis, but is not limited thereto.
[0122] Meanwhile, the microorganism having the ability to produce glutamate-series amino acids of the present application includes all of the natural wild-type microorganism itself, the microorganism having improved glutamate-series amino acid production ability by strengthening or weakening the activity of a gene related to the glutamate-series amino acid production mechanism, or the microorganism having improved glutamate-series amino acid production ability by introducing or strengthening the activity of an external gene.
[0123]
[0124] In this application, the term "cultivation" refers to growing the strain of this application under appropriately controlled environmental conditions. The cultivation process of this application can be performed using any suitable medium and culture conditions known in the art. This cultivation process can be easily adjusted and used by those skilled in the art depending on the selected strain. Specifically, the cultivation may be batch, continuous, and / or fed-batch, but is not limited thereto.
[0125] In this application, the term "medium" refers to a material containing nutrients as a main component necessary for culturing the microorganism of this application, and supplies nutrients and growth factors, including water, which is essential for survival and growth. Specifically, the medium and other culture conditions used for culturing the strain of this application may be any medium used for culturing general microorganisms without particular limitation. However, the microorganism of this application may be cultured under aerobic conditions in a general medium containing an appropriate carbon source, nitrogen source, phosphorus source, inorganic compound, amino acid, and / or vitamin, while controlling temperature, pH, etc. For example, a culture medium for a strain of the genus Corynebacterium can be found in the literature ["Manual of Methods for General Bacteriology" by the American Society for Bacteriology (Washington DC, USA, 1981)].
[0126] In the present application, the carbon source may include carbohydrates such as glucose, saccharose, lactose, fructose, sucrose, maltose, etc.; sugar alcohols such as mannitol, sorbitol, etc.; organic acids such as pyruvic acid, lactic acid, citric acid, etc.; amino acids such as glutamic acid, methionine, lysine, etc. In addition, natural organic nutrients such as starch hydrolysate, molasses, blackstrap molasses, rice winter, cassava, sugarcane bagasse, and corn steep liquor may be used, and specifically, carbohydrates such as glucose and sterilized pretreated molasses (i.e., molasses converted to reducing sugar) may be used, and other appropriate amounts of carbon sources may be used in various ways without limitation. These carbon sources may be used alone or in combination of two or more, but are not limited thereto.
[0127] The nitrogen source may include inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, ammonium nitrate, etc.; organic nitrogen sources such as amino acids such as glutamic acid, methionine, glutamine, etc.; peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steep liquor, casein hydrolysate, fish or its decomposition product, defatted soybean cake or its decomposition product, etc. These nitrogen sources may be used alone or in combination of two or more, but are not limited thereto.
[0128] The above-mentioned components may include potassium phosphate monobasic, potassium phosphate dibasic, or their corresponding sodium-containing salts. Inorganic compounds may include sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, calcium carbonate, etc. In addition, amino acids, vitamins, and / or suitable precursors may be included. These components or precursors may be added to the medium in batch or continuous manner, but are not limited thereto.
[0129] In addition, during the cultivation of the microorganism of the present application, compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid, etc. may be added to the medium in an appropriate manner to adjust the pH of the medium. In addition, during the cultivation, foaming may be suppressed by using an antifoaming agent such as fatty acid polyglycol ester. In addition, to maintain the aerobic state of the medium, oxygen or an oxygen-containing gas may be injected into the medium, or to maintain the anaerobic and microaerobic state, nitrogen, hydrogen, or carbon dioxide gas may be injected without gas injection, but is not limited thereto.
[0130] In the culture of the present application, the culture temperature can be maintained at 27 to 37°C, specifically 30 to 33°C, and the culture can be performed for about 20 to 120 hours, but is not limited thereto.
[0131] In the present application, the term "culture" means a culture solution, concentrated culture solution, dried product of culture solution, culture filtrate, concentrated culture filtrate, or dried product of culture filtrate obtained by culturing a specific microorganism in a culture medium, wherein the culture solution means that it contains a specific microorganism, and the culture filtrate means that it does not substantially contain a specific microorganism (here, substantially means that a specific microorganism separated by filtration or the like is excluded, but does not mean that the filtrate is completely free of microorganisms). The culture is not limited in its formulation, and may be, for example, a liquid, an emulsion, or a solid. Specifically, for the purpose of the present application, the culture may contain a glutamate series amino acid.
[0132] In this application, the term "fermentation" refers to a process in which microorganisms use their enzymes to decompose organic matter, but not to a putrefaction reaction. While fermentation and putrefaction occur through similar processes, if the resulting decomposition produces useful substances, it is called fermentation. If the resulting decomposition produces foul-smelling or harmful substances, it is called putrefaction.
[0133] In the present application, the method for obtaining a fermented product from the strain is not particularly limited, and can be obtained according to a method commonly used in the relevant technical field or a similar field.
[0134] In the present application, the term "fermentation" includes all kinds of materials including a fermentation product produced from the strain, such as not only the fermented material itself, but also a culture medium of the strain in which the strain and the culture coexist, a fermentation product obtained by filtering the strain from the culture medium, a fermentation product obtained by sterilizing the strain from the culture medium and filtering it, an extract obtained by extracting the fermentation product or a culture medium containing it, a diluted solution obtained by diluting the fermentation product or its extract, a concentrate obtained by drying the fermentation product or its extract, a lysate obtained by capturing and crushing the cells of the strain, etc.
[0135] In the method of the present application, any culture conditions and methods known in the art can be used to cultivate microorganisms. Those skilled in the art can easily adjust and use these culture processes according to the selected strain.
[0136] The glutamate series amino acids produced by the culture of the present application may be secreted into the medium or remain within the cells.
[0137]
[0138] In one specific example, the method for producing glutamate-based amino acids of the present application may further include, for example, a step of preparing a microorganism of the present application, a step of preparing a medium for culturing the strain, or a combination thereof (in any order), prior to the culturing step.
[0139] The method for producing glutamate-based amino acids of the present application may further include a step of recovering a target substance, specifically a glutamate-based amino acid, from the cultured microorganism, a culture of the microorganism, a fermented product of the microorganism, or the culture medium. The recovering step may be additionally included after the culturing step.
[0140] The above recovery may be performed by collecting the target glutamate series amino acid using a suitable method known in the art according to the culture method of the microorganism of the present application, for example, a batch, continuous or fed-batch culture method. For example, various chromatographies such as centrifugation, filtration, treatment with a crystallized protein precipitant (salting out method), extraction, ultrasonic disruption, ultrafiltration, dialysis, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography, HPLC or a combination thereof may be used, and the target substance, specifically, the glutamate series amino acid, may be recovered from the medium or microorganism using a suitable method known in the art.
[0141] Additionally, the method for producing glutamate-based amino acids of the present application may additionally include a purification step. The purification may be performed using any suitable method known in the art. In one example, when the method for producing glutamate-based amino acids of the present application includes both a recovery step and a purification step, the recovery step and the purification step may be performed sequentially or discontinuously, regardless of the order, or may be performed simultaneously or integrated into a single step, but is not limited thereto.
[0142] In the method of the present application, the weakening of the activity of the protein including the amino acid sequence of sequence number 1 and the glutamate series amino acids are as described in the other embodiments above.
[0143]
[0144] Another aspect of the present application provides a composition for producing glutamate-series amino acids, comprising a Corynebacterium genus microorganism having a glutamate-series amino acid production ability in which the activity of a protein comprising the amino acid sequence of SEQ ID NO: 1 of the present application is weakened compared to the intrinsic activity, a culture of the microorganism, a fermentation product of the microorganism, or a combination of two or more thereof.
[0145] The composition of the present application may further comprise any suitable excipient commonly used in compositions for producing glutamate-based amino acids, and such excipients may be, for example, but are not limited to, preservatives, wetting agents, dispersing agents, suspending agents, buffering agents, stabilizers, or isotonic agents.
[0146] In one specific example, each component present in the composition of the present application may be included in a microbiologically effective amount, or an amount that can be suitably present in the composition for production.
[0147] In the composition of the present application, the protein activity attenuation and glutamate series amino acids including the amino acid sequence of sequence number 1 are as described in the other embodiments above.
[0148]
[0149] Another aspect of the present application provides a use for producing glutamate series amino acids by a microorganism of the genus Corynebacterium having a glutamate series amino acid production ability that is weakened compared to the intrinsic activity of a protein comprising the amino acid sequence of SEQ ID NO: 1 of the present application.
[0150] In the purpose of the present application, the weakening of the activity of the protein comprising the amino acid sequence of SEQ ID NO. 1 and the glutamate series amino acids are as described in the other embodiments above.
[0151]
[0152] The present application will be described in more detail below through examples. However, the following examples are merely preferred embodiments intended to illustrate the present application and are therefore not intended to limit the scope of the present application. Furthermore, technical details not described herein can be readily understood and implemented by those skilled in the technical field of the present application or similar fields.
[0153]
[0154] Example 1: Construction of a recombinant vector for deletion of the NCgl2914 gene.
[0155] In order to confirm the correlation between the inactivation of a protein containing the amino acid sequence of sequence number 1 and the production ability of L-citrulline, a representative example of glutamate-based amino acids, a recombinant plasmid was constructed to delete a gene containing the nucleotide sequence of NCgl2914 encoding a protein containing the amino acid sequence of sequence number 1 on the chromosome of a Corynebacterium L-citrulline-producing strain.
[0156] First, in order to produce a recombinant vector capable of deleting the above gene on the chromosome of a microorganism of the genus Corynebacterium, four primers corresponding to sequence numbers 3, 4, 5, and 6 were synthesized.
[0157] Specifically, in order to delete the ORF region (SEQ ID NO: 2) of the NCgl2914 gene, primers of SEQ ID NOs: 3, 4, 5, and 6 were synthesized to have BamH I and Xba I restriction enzyme sites at the 5' and 3' ends. PCR was performed using the primers of SEQ ID NOs: 3, 4, 5, and 6 using the chromosomal DNA of Corynebacterium glutamicum ATCC13869 as a template. As a result, it was confirmed that DNA fragments corresponding to the front and back parts of the part where the protein encoded by the gene was encoded were amplified by 1000 bp each. The PCR conditions were as follows: denaturation at 95°C for 10 minutes, denaturation at 95°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 1 minute, repeated 30 times, and then polymerization was performed at 72°C for 10 minutes. Afterwards, PCR fragments were extracted using a gel purification kit (QIAGEN). The obtained recombinant arm gene fragment and the vector pDCM2 (WO WO2021-187781 A1) digested with BamH I and Xba I restriction enzymes were ligated using the Gibson assembly method (DG Gibson et al., NATURE METHODS, VOL.6 NO.5, MAY 2009, NEBuilder HiFi DNA Assembly Master Mix), and then transformed into E. coli DH5α, and plated on LB solid medium containing kanamycin (25 mg / l).
[0158] To select colonies transformed with the vector linking the target gene and pDCM2, PCR was performed with primers of SEQ ID NO: 7 (pDCM2_F) and 8 (pDCM2_R). A plasmid was obtained from the selected colony using a conventionally known plasmid extraction method and named pDCM2-△NCgl2914.
[0159]
[0160] Example 2: Production of L-citrulline-producing microorganisms
[0161] To construct an L-citrulline-producing microorganism, a vector was constructed that substitutes the glutamic acid at position 47 of the protein sequence of argR (ANU33619.1) with a stop codon. Using the genome of wild-type C. glutamicum ATCC 13869 as a template, the homologous recombinant A arm was amplified using the primer pair of SEQ ID NOs: 9 and 10, and the homologous recombinant B arm was amplified using the primer pair of SEQ ID NOs: 11 and 12. Thereafter, a plasmid was obtained using the same method as in Example 1, and this plasmid was named pDCM2-argR (E47*).
[0162] To produce a microorganism with improved L-citrulline production, a vector was constructed in which phenylalanine at position 68 of the protein sequence of argG (ANU33620.1) was replaced with a stop codon. Using the genome of C. glutamicum ATCC13869 as a template, the homologous recombinant A arm was amplified using the primers of SEQ ID NOs: 13 and 14, and the homologous recombinant B arm was amplified using the primers of SEQ ID NOs: 15 and 16. The plasmid was then obtained using the method described above, and this plasmid was named pDCM2-argG(F68*).
[0163]
[0164] Using the constructed pDCM2-argR(E47*) vector, wild-type C. glutamicum ATCC 13869 was transformed by electroporation (Appl. Microbiol. Biotechnol. (1999) 52:541-545), and then a second crossover process was performed to obtain a strain in which the 139th base sequence of argR was substituted from guanine (g) to thymine (t), and the 47th base sequence was substituted with a stop codon. PCR and base sequence analysis were performed using a pair of primers of SEQ ID NOs: 9 and 12 that can amplify the adjacent region including the position where the gene was inserted, and the genetic manipulation was confirmed. The microorganism thus obtained was named C. gl::argR*.
[0165] To construct a microorganism with further enhanced citrulline production from C. gl::argR*, the microorganism was obtained using the pDCM2-argG(F68*) vector as described above. PCR and base sequence analysis were performed using the primer pair of SEQ ID NOs: 13 and 16, which can amplify adjacent regions including the position where the gene was inserted, and the genetic manipulation was confirmed. The microorganism thus obtained was named C. gl::argR*_argG*.
[0166]
[0167] The primer sequences used are as shown in Table 1 below.
[0168]
[0169] Sequence number name sequence (5' -> 3') 9 Primer 9CGGTACCCGGGGATCCCTCGTGCGGAATTCGTGGAG 10 Primer 10ATCCAGCAGCAATTCAGACA 11 Primer 11CTGAATTGCTGCTGGATTAAGGCATCGATATCACCCA 12 Primer 12ATGCCTGCAGGTCGACCCTTCATTTTAAGTTCCTTG 13 Primer 13CGGTACCCGGGGATCCTTCATCGATAGGGTGGG 14 Primer 14GTACTCCTCAGCTTACTCATCCTTTGCATCAACA 15 Primer 15AGTAAGCTGAGGAGTACTGCCTGCCAACCATCAA 16 Primer 16ATGCCTGCAGGTCGACCGACTGGCTTGCCACCCT
[0170]
[0171] Example 3: Production of NCgl2914 gene knockout strain
[0172] Based on the L-citrulline producing strain, a strain lacking the gene comprising the nucleotide sequence of sequence number 2 was produced.
[0173] Specifically, the recombinant plasmid pDCM2-△NCgl2914 produced in Example 1 was transformed into the L-citrulline producing strain (C. gl::argR*_argG*) produced in Example 2 by homologous recombination on the chromosome (van der Rest et al., Appl Microbiol Biotechnol 52:541-545, 1999).
[0174] Afterwards, a second recombination was performed on a solid plate containing sucrose. The strain lacking the gene was confirmed through PCR using primers 3 and 6 from the above Corynebacterium glutamicum transformant that completed the second recombination. The recombinant strain was named Corynebacterium glutamicum C. gl::argR*_argG*_△NCgl2914.
[0175]
[0176] Example 4: Evaluation of L-citrulline production ability of NCgl2914 gene-deficient strain
[0177] To analyze L-citrulline production ability, the parent strain, Corynebacterium glutamicum C. gl::argR*_argG*, and the above-mentioned Corynebacterium glutamicum C. gl::argR*_argG*_△NCgl2914 strain were cultured using the following method.
[0178] Each strain was inoculated into a 250 ml corner-baffle flask containing 25 ml of the production medium described below and cultured at 33°C for 48 hours with shaking at 200 rpm. After completion of culture, the production of cell mass and L-citrulline was measured using HPLC.
[0179]
[0180] <Production medium (pH 7.2)>
[0181] 50 g of raw sugar, 30 g of (NH4)2SO4, 1 g of yeast extract, 1.1 g of KH2PO4, 1.2 g of MgSO4·7H2O, 0.2 g of L-arginine, 1 mg of biotin, 5 mg of thiamine hydrochloride, 5 mg of calcium-pantothenic acid, 15 mg of nicotinamide, 10 mg of MnSO4, 10 mg of FeSO4, 0.5 mg of ZnSO4, 0.5 mg of CuSO4, 30 g of CaCO3 (based on 1 liter of distilled water)
[0182] The above experiment was repeated twice, and the culture results (average values) are shown in Table 2 below.
[0183]
[0184] Strain OD562 Consumption (g / L) L-citrulline production (g / L) L-citrulline production increase rate (%) L-citrulline yield (%) Control strain C. gl::argR*_argG*60.950.02.8-5.5 NCgl2914 gene deletion strain C. gl::argR*_argG*_△NCgl291460.250.03.3176.7
[0185] As shown in Table 2 above, in the case of C. gl::argR*_argG*_△NCgl2914, which has the NCgl2914 gene deleted from the L-citrulline-producing strain Corynebacterium glutamicum C. gl::argR*_argG*, it was confirmed that the L-citrulline production ability increased by an average of 17% without affecting the cell body compared to the parent strain.
[0186] Therefore, it was confirmed that L-citrulline production ability can be improved by deleting the gene containing the nucleotide sequence of sequence number 2 in a microorganism of the genus Corynebacterium.
[0187]
[0188] From the above description, those skilled in the art will understand that the present application can be implemented in other specific forms without altering its technical concept or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of this application should be interpreted to include all changes or modifications derived from the meaning and scope of the following claims and their equivalents, rather than the detailed description above.
Claims
1. A method for producing a glutamate series amino acid, comprising the step of culturing a microorganism of the genus Corynebacterium having a glutamate series amino acid production ability that is weakened compared to the intrinsic activity of a protein containing the amino acid sequence of sequence number 1 in a medium.
2. A method according to claim 1, wherein the protein comprising the amino acid sequence of sequence number 1 is encoded by a gene comprising the base sequence of sequence number 2.
3. A method according to claim 1, wherein the microorganism of the genus Corynebacterium is Corynebacterium glutamicum.
4. A method according to claim 1, further comprising a step of recovering glutamate series amino acids from the cultured microorganism, a culture of the microorganism, a fermented product of the microorganism, or the culture medium.
5. A method according to claim 1, wherein the glutamate series amino acid is selected from the group consisting of citrulline, ornithine, arginine, glutamic acid, proline, and combinations thereof.
6. A composition for producing glutamate-series amino acids, comprising a Corynebacterium genus microorganism having a glutamate-series amino acid production ability in which the activity of a protein including the amino acid sequence of sequence number 1 is weakened compared to the intrinsic activity, a culture of the microorganism, a fermentation product of the microorganism, or a combination of two or more thereof.
7. Use of a microorganism of the genus Corynebacterium for producing glutamate-series amino acids, wherein the activity of a protein containing the amino acid sequence of sequence number 1 is weakened compared to the intrinsic activity of the protein and has a glutamate-series amino acid production ability.
Citation Information
Patent Citations
L-amino acid-producing bacterium and a method for producing an L-amino acid
US9644009B2
Method for producing l-tryptophan through enhancement of prephenate dehydratase activity
WO2021187781A1
Method for improving yield of L-glutamic acid synthesized by corynebacterium glutamicum
CN113881611A
Solar panel disassembly device
KR102589354B1
